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Introduction. Microalbuminuria is a powerful risk factor for
cardiovascular disease. It is not known whether genetic factors
play a role in the expression of microalbuminuria in population-
based samples.
Methods. Genome-wide variance components linkage-
analysis using 401 markers spaced at ∼10 cM was performed on
subjects from 330 extended families of the Framingham Heart
Study; a subanalysis was performed on families enriched for hy-
pertension. Urinary microalbumin was indexed to urinary cre-
atinine [urine albumin/creatinine ratio (UACR)] and was log-
transformed for analysis. Residuals of log-transformed UACR
adjusted for age, gender, body mass index, diabetes, systolic
blood pressure, hypertension treatment, smoking, and serum
creatinine were used in the linkage analysis.
Results. Among 1055 subjects (52% women), mean age
56 years, median UACR was 5.8 mg/g (11% >30 mg/g). The un-
adjusted heritability for UACR was 0.20; after multivariable ad-
justment, heritability was 0.16. The peak multivariable-adjusted
multipoint logarithm of odds (LOD) score was 2.22 on chromo-
some 8 at 135 cM (marker D8S1179); one LOD support interval
= 129 – 145 cM. In the subanalysis in families enriched for hy-
pertension (N = 676), the peak multivariable-adjusted LOD
score of 2.11 was observed at the same location.
Conclusion. We found suggestive linkage to urinary microal-
bumin on chromosome 8. At least one potential candidate gene
implicated in the pathogenesis of nephropathy (HAS2) lies in
this region. Further research is warranted to understand the
genetic basis of microalbuminuria.
Impaired kidney function is a risk factor for subse-
quent development of cardiovascular disease [1]. The eti-
ology of the elevated risk of cardiovascular disease seen
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in kidney disease might be related to the presence of mi-
croalbuminuria. Microalbuminuria has been shown to be
associated with incident cardiovascular disease [2, 3], car-
diovascular mortality [4–6], and all-cause mortality [7].
In the United States, it is estimated that the preva-
lence of microalbuminuria is roughly 11% [8]. Predictors
of microalbuminuria include age, ethnicity, serum creati-
nine, diabetes, hypertension [8], hyperglycemia [9], and
tobacco use [10].
Genetic factors are also likely to play a role in mi-
croalbuminuria. Segregation analysis suggests the pres-
ence of a major genetic effect on diabetic nephropathy
in the Pima Indians [11]. Familial clustering of microal-
buminuria has been seen in siblings of subjects with
diabetes [12], and albuminuria has been shown to be
heritable among the offspring of diabetic subjects [13].
In a genome-wide linkage analysis of families enriched
for hypertension, urinary microalbumin was shown to be
heritable (h2 = 0.49), and suggestive linkage [logarithm
of odds (LOD) scores 2.0 to 2.73] was found on chromo-
somes 12 and 19 [14]. However, it is not known if microal-
buminuria is heritable among community-based popula-
tions not selected for microalbuminuria risk factors. In
this analysis, we sought to test for heritability and linkage
for microalbuminuria in the Framingham Heart Study, a
community-based cohort study.
METHODS
The Framingham Heart Study began in 1948 with the
enrollment of 5209 men and women, 28 to 62 years of
age at study entry, with subjects undergoing repeat ex-
aminations every 2 years [15]. In 1971, 5124 men and
women were enrolled into the offspring cohort of the
Framingham Heart Study, which included the children or
spouses of the children of the original cohort. Offspring
subjects underwent examinations approximately every
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4 years; the design and methodology of the offspring co-
hort has been previously described [16].
The primary study sample included all participants with
urinary microalbumin and genotype information. A sub-
analysis was performed on families enriched for hyper-
tension. Probands were chosen from the pedigrees who
developed hypertension under the age of 60 years and
had an affected hypertensive sibling. Once identified, the
entire pedigree was brought into the analysis (N = 676).
The overall sample contained 330 pedigrees, contain-
ing 904 sibpairs, 70 avuncular pairs, 505 first-cousin pairs,
and 18 second-cousin pairs. The hypertension-enriched
sample contained 178 pedigrees, containing 636 sibpairs,
66 avuncular pairs, 415 first-cousin pairs, and 18 second-
cousin pairs. Pedigree size ranged from 1 to 36 in the
overall sample, and 1 to 24 in the hypertension-enriched
sample.
Details regarding the methods of risk factor measure-
ment and laboratory analysis have been described [17].
Each examination included an extensive cardiovascular
disease assessment, 12-lead electrocardiogram (ECG),
and blood testing. Subjects with a systolic blood pressure
≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg (av-
erage of two readings taken by the examining physician)
or receiving medication for treatment of hypertension
were defined as hypertensive. Smoking status was defined
as smoking 1 or more cigarettes/day in the year preceding
the examination. Body mass index was defined as weight
(kilograms) divided by the square of height (meters).
Diabetes was defined as a fasting glucose > 125 mg/dL
(7.0 mmol/L) or on treatment. Serum and urine crea-
tinine were measured using the modified Jaffe´ method.
Urinary microalbumin was measured in 1995 to 1998 by
a single-void urine sample. Urine albumin concentration
was measured by immunoturbimetry (Tina-quant Albu-
min assay) (Roche Diagnostics, Indianapolis, IN, USA).
Urine creatinine was measured using the modified Jaffe´
method by a morning single-void urine sample. Urinary
microalbumin was indexed to urinary creatinine as the
urine albumin/creatinine ratio (UACR) in order to ac-
count for differences in urine concentration; this variable
was the primary urinary albumin excretion trait in our
analysis. The UACR is a validated, reliable single-sample
measure of urinary albumin excretion that is highly cor-
related with albumin excretion rates assessed by 24-hour
urine collection [18, 19].
For genotyping, anonymous microsatellite marker
leukocyte DNA was extracted from 5 to 10 mL of
whole-blood or buffy coat specimens using a standard
protocol [20]. Aliquots of DNA from members of the
largest Framingham Heart Study families were sent
in four batches to the Mammalian Genotyping Ser-
vice Laboratory at the Marshfield Clinic (Marshfield,
WI, USA). The screening set and genotyping protocols
are available at the website of the Center for Medi-
cal Genetics, Marshfield Medical Research Foundation
(http://research.marshfieldclinic.org/genetics/). A 10 cM
density genome-wide scan was performed (marker set
9, average heterozygosity 0.77). Genotype data clean-
ing, including verification of family relationships and
Mendelian inconsistencies, have been previously de-
scribed [21].
Statistical analysis
UACR was log-transformed to normalize its distribu-
tion. Using SAS (SAS Institute, Inc., Cary, NC, USA),
gender-specific residuals from regression analyses were
computed. Gender-specific residuals were used to ac-
count for gender differences in UACR and environmental
predictors. Two sets of residuals were computed corre-
sponding to the adjustments of (1) age and (2) age, body
mass index, tobacco use, diabetes, systolic blood pressure,
hypertension treatment, and serum creatinine. A resid-
ual value greater than 2.5 standard deviations from the
mean was reduced to the 2.5 standard deviations value
(i.e., “winsorized”) to reduce the skewness and kurtosis
of the data [22]. Variance components linkage analysis
is sensitive to violations of the assumption of normally
distributed data [23]. This sensitivity can cause an error
rate in excess of the specified error rate. Winsorizing is
an accepted technique used in genetic analyses to reduce
the skewness and kurtosis of the data.
Variance components models [24, 25], implemented in
SOLAR [24] and Genehunter [26] was used to perform
the heritability and genome-wide linkage analyses, re-
spectively, on UACR as a quantitative trait. Heritability
is defined as the proportion of variability in the trait at-
tributable to the additive effect of genes, and represents
the contribution of both genes and early common envi-
ronment on trait levels. The underlying model assumes
that variation in the trait can be partitioned into genetic
and random environmental components. Variance com-
ponents linkage analysis uses the genotype information
at a locus to decompose variance in the phenotype into
a genetic component attributable to the locus known as
a quantitative trait locus (QTL), a polygenic component,
and an environmental component. Genotype informa-
tion at a QTL is characterized by the probability that two
related individuals share 0, 1, or 2 alleles identical by de-
scent (IBD).
All variance components were estimated by maximum
likelihood. Linkage was tested by a likelihood ratio test
in which the hypothesis that the QTL variance compo-
nent is equal to zero (e.g., has no genetic association with
the trait) was compared to it being greater than zero.
The resulting chi-square statistic was converted to a tra-
ditional LOD score by dividing by 2 ∗ ln(10). The LOD
score associated with a marker or region is an estimate
of the probability that the marker lies close to, or the
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Mean (SD) Mean (SD)
Characteristic (N = 1055) (N = 676)
Age 56 ± 10 58 ± 10
% Female 52 50
Urinary albumin/creatinine 5.8 (2.4, 14.1) 6.7 (2.7, 15.9)
ratioa mg/g
Urinary albumin/creatinine 11 15
ratio >30 mg/g %
Serum creatinine mg/dL 1.13 ± 0.22 1.15 ± 0.24
Body mass index kg/m2 28.2 ± 5.5 28.9 ± 5.6
Systolic blood pressure mm Hg 125 ± 18 130 ± 19
Hypertension% 35 49
Hypertension treatment % 24 34
Diabetes % 8 11
Current smoking % 17 15
aExpressed as median (25th and 75th percentiles).
Table 2. Crude, age-adjusted, and multivariable-adjusted heritability





Fully adjusteda 0.16 0.20
aHeritability for gender-specific residuals for urinary albumin/creatinine ratio,
adjusted for age, body mass index, tobacco use, diabetes, systolic blood pressure,
hypertension treatment, and serum creatinine.
region contains, a gene associated with elevated levels of
the quantitative trait. LOD scores were interpreted using
common thresholds to define genome-wide significance
[27].
RESULTS
Overall, 1055 subjects were available for analysis. Char-
acteristics of the sample overall and the hypertensive-
enriched subgroup are shown in Table 1. Subjects were
middle-aged, about half were women, and the median
UACR was slightly higher in the hypertensive-enriched
subgroup than in the overall sample.
Crude, age-gender adjusted, and multivariable ad-
justed heritabilities for the overall analysis and
hypertension-enriched subanalysis are presented in
Table 2. Multivariable adjustment only minimally atten-
uated the heritability of UACR. Multivariable adjusted
heritability estimates were slightly higher among the
hypertension-enriched sample (0.20) than in the over-
all sample (0.16). Thus, about 20% of the variability in
UACR was attributable to genetic influences.
Table 3 presents all LOD scores >1.0 for the over-
all sample and the hypertension-enriched sample. The
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Fig. 1. Multipoint logarithm of odds (LOD) score for the overall sam-
ple and the hypertension (HTN)-enriched sample for chromosome 8.
Table 3. Logarithm of odds (LOD) scores >1.0 for urinary
albumin/creatinine ratio
Overall sample Hypertension sample
Location LOD Location LOD
Chromosome cM score Chromosome cM score
1 24.4 1.15 1 21.6 1.16
5 160 1.50 5 160 1.13
8 135 2.22 8 135 2.11
12 83 1.07 12 85.4 1.70
chromosome 8. The peak multipoint LOD score in the
fully adjusted model was 2.22 on chromosome 8 at 135
cM (nearest marker D8S1179), one LOD support inter-
val = 129 cM – 145 cM. In the hypertension-enriched
sample, the peak multipoint LOD score was 2.11 at the
same location (Fig. 1).
DISCUSSION
In a community-based sample not selected for kidney
disease or its risk factors, urinary microalbumin demon-
strates suggestive evidence for linkage to a novel locus
on chromosome 8.
These data are among the first population-based
genome-wide linkage analyses to suggest a specific ge-
nomic region linked to levels of urinary microalbumin.
Another linkage analysis was performed in subjects en-
riched for hypertension, which demonstrated a heritabil-
ity of UACR of 0.49 and a peak LOD score of 2.73 on
chromosome 19 [14]. We did not confirm this linkage
peak on chromosome 19 in our sample. Other genome-
wide linkage analyses have been performed looking at
more severe nephropathy in families with large numbers
of affected individuals. Linkage analysis was performed
among sibpairs with diabetic nephropathy (UACR ≥500
mg/g, diabetes duration of at least 10 years, and dia-
betic eye disease), and suggestive evidence for linkage
was found on chromosome 10p [28]. In a large African
American family (18 out of 23 family members affected)
with hypertensive nephropathy, a LOD score of 5.4 on
chromosome 9q31-32 was observed [29]. A large family
Fox et al: Linkage to microalbuminuria 73
with a dominant pattern of inheritance of focal segmental
glomerulosclerosis was found to have a peak LOD score
of 12.28 on chromosome 19q13 [30]; familial nephrotic
syndrome was found to map to this same locus [31]. In
a large family with autosomal-dominant disease charac-
terized by hypertension, nephropathy, and progressive
kidney failure, a peak LOD score of 4.71 was found
on chromosome 1q21 [32]. The very high LOD scores
among pedigrees enriched with a highly selected nephro-
pathic phenotype offers promise for mapping of loci for
severe nephropathy. However, the diverse phenotypes
and diverse linkage results in these studies highlight that
phenotypic heterogeneity in renal disease is likely to be
associated with substantial genetic heterogeneity. Our
data suggest that there may also be genetic contributions
to milder forms of renal dysfunction, but this is likely
also to be associated with genetic heterogeneity. Repli-
cation of our linkage signal for UACR on chromosome 8
in other samples is required to more firmly establish the
importance of this region as potentially harboring a can-
didate gene for urinary albumin excretion. Chromosome
8q does contain at least one potential candidate gene for
nephropathy, hyaluron synthase 2 (HAS2). HAS2 plays
a role in the synthesis of hyaluron, a connective tissue
polysaccharide found in the renal proximal epithelial cells
[33]. Association studies with this and other putative can-
didate genes will be required to further explore the ge-
netic basis of urinary albumin excretion.
While selected pedigree linkage analyses have yielded
promising results regarding mapping of loci for
nephropathy, it is uncertain if these results will be gener-
alizable to community-based study samples.
In our study, we performed linkage in both the overall
sample, as well as in a subsample enriched for hyperten-
sion. Despite a twofold reduction in sample size, the peak
LOD score is preserved at the same locus observed in the
overall analysis, suggesting that much of the linkage signal
observed in the overall sample may be due to the genetic
effects of microalbuminuria in the setting of hypertensive
disease.
In other work, we found peak LOD scores for serum
creatinine, glomerular filtration rate, and creatinine clear-
ance of 2.28 at 176 cM on chromosome 4, 2.19 at 78 cM
on chromosome 4, and 1.91 at 103 cM on chromosome
3, respectively [34]. It is not surprising that we found dif-
ferent regions of linkage for serum creatinine, glomeru-
lar filtration rate, and creatinine clearance as compared
to microalbuminuria, since the traits represent different
phenotypes [35].
Certain limitations of our study deserve attention. We
used UACR from spot urines as an estimate of protein
excretion instead of measuring 24-hour urine, which may
produce some misclassification by albumin excretion sta-
tus, although UACR on spot urine has been shown to
approximate 24-hour urine collections [18]. The predom-
inantly Caucasian population that comprises the majority
of the Framingham cohort may limit the generalizability
of our findings. However, cardiovascular risk factor re-
lationships from Framingham have been validated in six
ethnically and geographically diverse cohorts, and were
found to be applicable in other populations, reinforcing
the representativeness of our data [36]. Because our phe-
notype information was not collected until 1995, we may
have incurred a survival bias, since subjects with a greater
genetic predisposition to more severe kidney disease may
have died prematurely. However, this loss would likely at-
tenuate our results. Lastly, our peak LOD score of 2.22 is
suggestive for linkage, and may represent a false positive
result.
CONCLUSION
Suggestive evidence exists in Framingham Heart Study
families for linkage to a novel locus on chromosome 8q
to levels of urinary microalbumin excretion. This locus
may reflect existence of a candidate gene or genes for mi-
croalbuminuria, or for urinary microalbumin excretion
associated with hypertension. Further research is neces-
sary, especially replication of linkage in other samples, to
better understand the genetics involved in the develop-
ment of nephropathic kidney disease.
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